NewsPR Newswire
TransCode Therapeutics to Present Phase 1a Clinical Trial Data for TTX-MC138 at ESMO Congress 2026
· Published
Article summary
Poster presentation to highlight the Phase 1a clinical evaluation of TTX-MC138 in patients with advanced solid tumors BOSTON, Oct. 19, 2026 — TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering immuno-oncology and RNA-based therapeutics for the...
An excerpt from the original article.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…